Multiple Sclerosis Treatment Guidelines

Approved Infusion Therapies for MS

• The American Academy of Neurology recommends natalizumab as escalation therapy for patients with breakthrough disease activity on first-line therapy, particularly if JC virus antibody-negative 1, 2
• The National Multiple Sclerosis Society indicates ocrelizumab is approved for both relapsing-remitting MS and primary progressive MS, representing the only specific treatment approved for primary progressive disease 2
• The European Committee for Treatment and Research in Multiple Sclerosis considers alemtuzumab a high-efficacy DMT option for escalation therapy in highly active MS 2

Appropriate MS Treatment Options

• High-efficacy infusion therapies should be considered for patients with highly active MS who have failed standard or high-efficacy DMT for ≥6 months, according to the American Academy of Neurology 2
• The National Multiple Sclerosis Society recommends Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for aggressive relapsing-remitting MS refractory to high-efficacy disease-modifying therapies, using intermediate-intensity conditioning 1

Clinical Recommendation

• The American Academy of Neurology, National Multiple Sclerosis Society, and European Committee for Treatment and Research in Multiple Sclerosis do not support the use of [MEDICATION] for MS treatment, as it is not included in any treatment algorithm for MS 1, 2, 3, 4, 5, 6, 7